Stock Analiz

INSMED Inc (INSM) financials: revenue, earnings and cash flow

Fiscal 2016–2025 + TTM · from SEC filings · data as of November 13, 2026

Summary

Net income in fiscal 2025 was -$1.3B, a net margin of -210.5%; the best year in this period was 2016 with -$176M.

Over the twelve months to September 30, 2026, revenue was $1.5B and net income -$606M.

Free cash flow was -$968M in fiscal 2025 and positive in 0 of the 10 years shown.

The diluted share count rose 222% over the period (dilution).

Revenue, profit and cash flow by year

Revenue
2016: $0162017: $0172018: $10M182019: $136M192020: $164M202021: $188M212022: $245M222023: $305M232024: $364M242025: $606M25$606M
Net income
2016: -$176M162017: -$193M172018: -$324M182019: -$254M192020: -$294M202021: -$435M212022: -$482M222023: -$750M232024: -$914M242025: -$1.3B25-$1.3B
Free cash flow
2016: -$151M162017: -$163M172018: -$271M182019: -$293M192020: -$226M202021: -$371M212022: -$410M222023: -$550M232024: -$706M242025: -$968M25-$968M
EPS (diluted)
2016: $-2.85162017: $-2.89172018: $-4.22182019: $-3.01192020: $-3.01202021: $-3.88212022: $-3.91222023: $-5.34232024: $-5.57242025: $-6.4225$-6.42

Income statement

Fiscal yearTTM2025202420232022202120202019201820172016
Revenue$1.5B$606M$364M$305M$245M$188M$164M$136M$10M$0$0
Gross profit$1.3B$483M$278M$240M$190M$144M$125M$112M$7M$0$0
Operating income-$564M-$1.2B-$878M-$710M-$457M-$375M-$265M-$235M-$307M-$189M-$173M
Net income-$606M-$1.3B-$914M-$750M-$482M-$435M-$294M-$254M-$324M-$193M-$176M
EPS (diluted)$-2.81$-6.42$-5.57$-5.34$-3.91$-3.88$-3.01$-3.01$-4.22$-2.89$-2.85
R&D$944M$771M$598M$571M$398M$273M$181M$132M$145M$110M$123M
Revenue growth—+66.7%+19.2%+24.4%+30.2%+14.6%+20.5%+1287.6%———

Cash flow

Fiscal yearTTM2025202420232022202120202019201820172016
Operating cash flow-$596M-$935M-$684M-$536M-$400M-$363M-$219M-$251M-$258M-$160M-$147M
Capital spending-$32M-$33M-$22M-$13M-$10M-$7M-$6M-$42M-$13M-$3M-$4M
Free cash flow-$628M-$968M-$706M-$550M-$410M-$371M-$226M-$293M-$271M-$163M-$151M
Dividends paid—$0$0$0$0$0$0$0$0$0$0
Buybacks———————————
Stock-based pay$167M$153M$97M$75M$58M$46M$36M$27M$26M$18M$18M

Balance sheet

Fiscal yearTTM2025202420232022202120202019201820172016
Cash—$1.4B$1.4B$780M$1.1B$717M$533M$487M$495M$381M$163M
Debt—$568M$1.1B$1.2B$1.2B$831M$483M$490M$450M$56M$55M
Equity—$739M$285M-$332M$88M$410M$276M$262M$208M$361M$154M
Total assets—$2.3B$2.0B$1.3B$1.7B$1.2B$796M$742M$605M$462M$238M
Shares (diluted)219M199M164M140M123M112M98M85M77M67M62M

Margins and returns

Fiscal yearTTM2025202420232022202120202019201820172016
Gross margin84.4%79.7%76.4%78.5%77.5%76.6%75.8%82.3%75.4%——
Operating margin-37.1%-205.6%-241.5%-232.5%-186.4%-199.0%-161.3%-172.4%-3124.9%——
Net margin-39.9%-210.5%-251.2%-245.6%-196.3%-230.6%-178.9%-186.4%-3297.2%——
FCF margin-41.3%-159.5%-194.1%-180.1%-167.2%-196.6%-137.2%-214.6%-2756.2%——
ROIC—-75.3%-48.7%-64.8%-28.6%-30.1%-27.6%-24.7%-36.9%-45.3%-65.4%
ROE—-172.8%-320.2%225.8%-547.5%-105.9%-106.6%-97.2%-155.7%-53.4%-114.1%

Frequently asked questions

What is INSMED’s annual revenue?

$606M in fiscal 2025 and $1.5B over the twelve months to September 30, 2026.

How much profit does INSMED make?

Net income was -$1.3B in fiscal 2025 (net margin -210.5%).

Is INSMED’s revenue growing?

Yes: revenue rose 66.7% in fiscal 2025 compared with the year before.

From the company’s 10-K and 10-Q filings with the SEC; per-share figures adjusted for stock splits. Rebuilt daily. Not investment advice.